Highlight-Mandate

• Represents Polpharma in a landmark EU regulatory dispute over generic access to Tecfidera, involving novel interpretations of pharmaceutical law and data exclusivity. Following a major General Court victory, later overturned on appeal, the team continues to coordinate multi-jurisdictional litigation and regulatory engagement. The case has earned multiple LMG Life Sciences “Impact Case of the Year” awards.
  
• Represents STADA Arzneimittel and its subsidiary EG in one of Belgium’s largest ongoing patent infringement cases, brought by Bayer over the dosing patent for rivaroxaban. The high-profile dispute, involving complex patent, regulatory, contractual and antitrust issues, spans multiple proceedings and has been recognised as an “Impact Case of the Year.”
  
• Advised Myocene, a Belgian medtech startup company specialising in measuring muscle fatigue, and its current shareholders in a Series A venture capital round of financing.
  

Highlight-Mandate

• Represented Aloe Vera of Europe, the largest manufacturer of Aloe vera drinks in the world, in litigation before the EU General Court, including a request for suspension, against a Commission Regulation banning HADs, a substance that is found naturally in most plants, for an infringement of the precautionary principle.
  
• Advising The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) on a host of important issues, such as regulatory data protection and other incentives, pricing and market access, transparency, paediatrics, and especially the revision of the orphan medicines regime.
  
• Acting as the legal advisor to the vaccines working group of the IFPMA. This work involved seasonal influenza, as well as the Pandemic Influenza Preparedness Framework (PIP) under the umbrella of the WHO.
  

Highlight-Mandate

• Defended Harvard University, Massachusetts General Hospital, and Ethicon Endo-Surgery against claims by Belgian and Dutch universities over a European patent application for Akkermansia bacteria-based weight loss therapy.
  
• IP due diligence in the framework of Axiles Bionics Series A funding round.
  
• Acting for the State of Hungary in a dispute with Pfizer regarding the deliveries of COVID-19 vaccines.
  

Highlight-Mandate

• Advised KCE on legal and regulatory strategies for advanced therapy medicinal products, helping non-profit and academic developers overcome obstacles, shape ATMP policy, and expand patient access.
  
• Advised Sightera Biosciences on drafting and negotiating its in-licensing agreement for oncology patents, AI software and data with the University of Antwerp and Antwerp University Hospital.
  
• Advised Boehringer-Ingelheim on a daily basis across a broad range of regulatory compliance matters, including the promotion of human and veterinary medicinal products, design of discount strategies, compliance with Belgian and EU regulations, and effective engagement with the FAMHP, while also advising on patient support programs.
  

Highlight-Mandate

Highlight-Mandate

• Acting for Belgian Association of Consumer Healthcare Industry and Kenvue (formerly the Consumer Healthcare division of Johnson & Johnson) in ongoing legal proceedings before the Belgian Council of State seeking annulment of a Belgian Royal Decree amending the Belgian rules on the storage and sale of poisonous and toxic substances.
  
• Successfully represented Schwabe in cease-and-desist proceedings before the President of the Dutch-language Brussels Enterprise Court against Orifarm, which is one of the main parallel traders in Europe.
  

Highlight-Mandate

• Advised EQT Life Sciences on a substantial minority investment – including on the key regulatory aspects – in PanTera, one of the most promising Belgian growth companies that specialises in next-generation radiopharmaceuticals.
  

Highlight-Mandate

• Represents Novartis regarding the Belgian Health Insurance Institute’s initiative to decrease the price and reimbursement basis of its medicinal products Certican® and Votubia®, given the availability on the market of generic versions of still another Novartis product Afinitor®.
  
• Regularly advises Mitsui AgriScience, a key global agrochemical player within the Mitsui & Co. group, on compliance with EU and Belgian regulations for plant protection products and biostimulants.
  
• Representing Bayer in legal proceedings before the Brussels Dutch-language first instance court against the Belgian State and the Health Insurance Institute over a pricing and reimbursement dispute concerning a Bayer medicinal product affected by the market presence of generics.
  

Highlight-Mandate

• Advising the European Medicines Verification Organisation (EMVO) on regulatory compliance, data protection, corporate and policy matters related to the Falsified Medicines Directive. Its work helps maintain the integrity and evolution of the European Medicines Verification System, ensuring alignment with evolving standards such as GAMP5® and supporting EMVO’s strategic operations across the EU.
  
• Advising Acadia Pharmaceuticals on the European launch of trofinetide, guiding strategy across reimbursement, promotion, pharmacovigilance, quality management, supply chain design and commercial partnerships. Work spans multiple jurisdictions, addressing regulatory grey areas and divergent national rules, and developing tailored, compliant solutions for a smooth and effective EU market entry.
  
• Advising Nipro on a wide range of regulatory and legal matters across its medical device and chemical product portfolio, including revising its quality management system, assessing borderline product classifications, handling commercial contracts, and engaging with authorities and notified bodies. It also supports the implementation of CAPAs to ensure compliance with evolving regulatory standards.
  

Highlight-Mandate

Highlight-Mandate

• Successfully represented AbbVie in the first Dutch human rights-based class action alleging excessive pricing of a patented medicine. The case highlights the firm’s ability to coordinate cross-border and cross-disciplinary teams across multiple practice groups and offices to address complex, high-profile pharmaceutical litigation.
  
• Represents BioMarin in a wide array of regulatory, legal and litigation matters. These include assisting with: national pricing and reimbursement matters; the performance of clinical trials and post-market studies; sector-specific healthcare compliance and data privacy matters; M&A; IP; litigation; trade and tariffs; and other regulatory matters.
  
• Successfully represented Biocom California in the landmark Illumina case (C-611/22) in which the European Court of Justice invalidated the European Commission’s unlawful new Article 22 policy asserting jurisdiction over transactions falling below EU and national notification thresholds.
  

Highlight-Mandate

• Advised the founders of ATB Therapeutics in securing €54 M in an equity round co-led by EQT Life Sciences and MRL Ventures Fund (MRLV), alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and other investors.
  
• Provided IP advice to Exphar, a leading generics laboratory focused on developing accessible pharmaceutical products for the African market, in the structuring of a new supply chain.
  
• Advised Samsara Vision, Inc. on EU-wide regulatory issues for supply chain and cross-border registrations, and provided multi-jurisdictional guidance on national rules for KOL engagement, tenders, clinical investigations, and consulting arrangements across Europe.
  

Highlight-Mandate

• Advised on developing an application to streamline sponsorship of healthcare and veterinary professionals at scientific and commercial events, translating complex EU and Belgian compliance rules into practical approval thresholds. The project included analysing veterinary sector rules and supporting future industry advocacy, and was delivered with German colleagues in a cross-border context, with Belgium as the pilot market.
  
• Advised Sequana Medical on a series of complex financing transactions totalling over €10 million, including convertible bridge loans, credit facility restructurings, and a €3 million loan with deferred debt service.
  
• Represented multiple Menarini Group entities in international litigation against Dishman Carbogen Amcis Ltd, an India-based pharmaceutical and chemical manufacturer. The dispute concerns the manufacture and supply of chemical components and active pharmaceutical ingredients.
  

Highlight-Mandate

• Advised MedTech Europe on its procurement and competition-related questions.
  
• Assisting Synlab in various matters: regulatory, corporate/M&A, restructuring, real estate, tax, commercial, and employment.
  
• Assisted Faceland in regulatory matters, notably in a matter involving marketing law (use of social media and influencers).
  

Highlight-Mandate

• Advised longstanding client Nipro on a wide range of medical device regulatory matters under the MDR and IVDR, drafting and reviewing LSHC-related agreements, and supporting global software commercialisation.
  
• Advising biotech spin-off from UCLouvain and Wageningen University, Akkermansia Company SA (TAC), on the full suite of IP and commercial contracts relating to the development and launch of novel food and supplement products based on the Akkermansia muciniphila strain.
  
• Acting as a trusted legal advisor to specialist LSHC investment firm Bioqube Ventures, based in Europe and the US. Bioqube Ventures sources, finances and develops innovative therapeutic assets and technologies.
  

Highlight-Mandate

Highlight-Mandate

• Advised Galapagos NV on the Belgian and Dutch tax aspects of its strategic partial demerger into two listed entities, part of a rare and complex cross-border reorganisation.
  
• Advised EQT on its acquisition of CluePoints SA, a leading AI-driven clinical data review platform, through a competitive cross-border auction process.
  
• Advising Pfizer on its high-stakes dispute with several EU Member States regarding payment and delivery obligations under the EU’s Covid-19 vaccine purchase agreement, including litigation before the Brussels Court and strategic advice on contractual rights across the EU.
  

Highlight-Mandate

Highlight-Mandate

• Advising Formycon in the Belgian part of cross-border patent litigation in relation to biosimilar medicinal products.
  
• Represented Doctor Anytime, a start-up that developed into a major online platform for medical appointments and healthcare services. Privacy issues are being litigated before the Brussels Court of Appeal against the Belgian privacy authority following a complaint from non-participating doctors acting on behalf of a competing service. The importance of these services (now authorised, but regulated) has increased heavily since the pandemic.
  
• Assisted GE HealthCare Technologies Inc., a leading global medical technology, pharmaceutical diagnostics, and digital innovator with a market cap of c.$40bn, with the acquisition of the American-based MIM Software Inc.
  

Highlight-Mandate

• Assisted Sanofi on its equity investment (series D) in Agomab NV. French multinational pharmaceutical company Sanofi, together with equity investor Invus, and other existing shareholders invested 89 million dollar.
  
• Assist Mylan, a global leader in generic and biosimilar pharmaceutical products, in proceedings before the Court of justice of the EU against the European Commission in relation to an exemption granted to one of its competitors on the market exclusivity of its product Tobi Podhaler as an orphan medicinal product. (containing the active substance “tobramycin”
  
• Advised PSG Equity on the acquisition of a stake in the Corilus group, a leader in medical software solutions for the primary care market in Belgium. The transaction also consisted of a re-investment by Rivean Capital, following which both PSG Equity and Rivean Capital have become joint partners to support Corilus’ next stage of growth.
  

Highlight-Mandate

• Representing Abbott in various UPC and national cases to protect the intellectual property relating to their highly profitable continuous glucose monitoring Free Style Libre devices and systems.
  
• Representing Viatris in the Belgian proceedings as well as in some of the proceedings before the General Court relating to patent infringement and market authorisation in the context of the generic launch of Dimethyl fumarate Mylan, the generic version of Biogen’s Tecfidera product, raising very interesting issues, in particular in relation to data exclusivity.
  
• Representing the Dana-Farber Cancer Institute in proceedings against the Belgian State relating to their SPC applications. These proceedings raise various interesting questions relating to the SPC Regulation.